Europe Human Primary Cells Market By Type (Blood (peripheral) cells, Endothelial cells, Epithelial cells, Fibroblast cells, Hepatocyte cells, Keratinocyte cells, Melanocyte cells, Pancreatic cells, Smooth muscle cells, Skeletal cells, Adipocyte cells), By Application (Medical, Clinical), Industry Trends, Estimation & Forecast, 2018 - 2025

Check Today's Best Price

$3500 Buy Now
Europe Human Primary Cells Market is expected to grow with a CAGR of 6.1% during the forecast period of 2018 to 2025.
  • Market Overview:

    Europe is a region where strict regulations are implemented for the safety and well-being of any kind of living form. The sedentary lifestyle of people in the region has led to an increase in the prevalence of various curable and non-curable chronic diseases. Several diseases have found to affect the human organ systems such as heart, vascular system, blood, kidneys, skeleton, and musculature. The manipulation of human cells for cell and tissue replacement therapies holds great importance in the treatment of degenerative disease and injuries affecting the human organ systems. In the European Union (EU), gene- and cell-based therapies are defined as advanced therapy medicinal products. According to certain research, more than 4000 stem cell-based therapies are registered globally with the US NIH clinical trials database, of which a significant percentage (23%) of activity is within Europe. These clinical trials have a commercial sponsorship, with small- and medium-sized enterprises ascending in the European market. Moreover, various collaborative research projects, under the 6th Framework Programme (2002-2006) are funded by the European Union. These projects include stem cells that are studied or used as discovery means or biological tools. The clinical trials conducted in the EU are currently being governed by the Clinical Trials Directive, which will be overtaken by the Clinical Trial Regulation from 2019.

    Regulations of human cell research in Europe vary from country to country. In the UK, the Medicines and Healthcare Products Regulatory Agency (MHRA) is responsible for authorizing clinical trials and inspecting and issuing the manufacturer’s license for an Investigational Medicinal Product. In addition, the ethical approval is delivered by a Research Ethics Committee (REC), allowing an organization or researcher, in countries such as Wales, England, and Northern Ireland to procure, test, process, store, distribute and import/export tissues and cells, including cell lines. On the other hand, Spain has a comprehensive regulatory framework for stem cell research, with a series of laws and regulations applied to different aspects of research. There are two separate commissions with different functions in relation to stem cell research, such as guarantees commission for the donation and use of human cells, and tissues and national commission on assisted human reproduction. In Germany, the use of embryos for research is heavily restricted under the Embryo Protection Act, 1991, making the derivation of embryonic stem cell lines a criminal offence. Any applications to import stem cell lines for research must be approved by the Central Ethics Commission for Stem Cell Research (ZES), which comprises of scientists, physicians and experts in ethics. Whereas in France, while performing a research on human cells, two pieces of legislation must be taken into consideration. Firstly, the rules regarding research on human participants must be fulfilled (a written protocol must be submitted including the information document and the consent form). Secondly, specific rules apply to the collection of human material (including bio-banking activities).

    Major pharmaceutical companies are investing in gene- and cell-based therapy development in the European Union, however, recently a drop in the number of clinical trials held in the UK has been witnessed. This is expected to hamper the growth of human primary cells market in region.
    The report provides detailed qualitative and quantitative analysis of the Europe human primary cells market. Market size and forecast in terms of value and volume has been provided for the period – (2017 – 2025), for the segments namely type, and application in each of the major regions.

    Europe Human Primary Cells Market Segmentation

    By Type

    • Blood (peripheral) cells
    • Endothelial cells
    • Epithelial cells
    • Fibroblast cells
    • Hepatocyte cells
    • Keratinocyte cells
    • Melanocyte cells
    • Pancreatic cells
    • Smooth muscle cells
    • Skeletal cells
    • Adipocyte cells

    By Application

    • Medical
    • Clinical

    By Country

    • U.K.
    • France
    • Germany
    • Italy
    • Spain
    • Benelux
    • Russia
    • Rest of Europe

    keyboard_arrow_up
  • CHAPTER 1. INTRODUCTION
    1.1. RESEARCH METHODOLOGY
    1.1.1. ERC desk research
    1.1.2. ERC data synthesis
    1.1.3. Data validation and market feedback
    1.1.4. ERC data sources

    CHAPTER 2. EUROPE HUMAN PRIMARY CELL MARKET KEY INSIGHTS
    2.1. RESEARCH SUMMARY AND SCOPE 25
    2.2. HUMAN PRIMARY CELL PRODUCTION (MILLION CELLS), 17–25
    2.2.1. Europe Human Primary Cells Production (Million Cells) (17-25)
    2.3. HUMAN PRIMARY CELL CONSUMPTION (MILLION CELLS), 17–25
    2.3.1. Europe Human Primary Cells Consumption (Million Cells) (17-25)
    2.4. HUMAN PRIMARY CELL REVENUE (MILLION USD), 17-25
    2.4.1. Europe Human Primary Cells Revenue (Million USD) (17-25)

    CHAPTER 3. HUMAN PRIMARY CELL MARKET DYNAMICS
    3.1. MARKET DETERMINANTS

    CHAPTER 4. EUROPE HUMAN PRIMARY CELL MARKET BY TYPE
    4.1. SEGMENT OUTLINE AND MARKET SHARE BY TYPE
    4.2. EUROPE HUMAN PRIMARY CELL MARKET REVENUE (MILLION USD) & PRODUCTION VOLUME (CELLS) BY TYPE, 17-25
    4.2.1. Europe Human Primary Cell Market Revenue (Million USD) By Type, 17-25
    4.2.2. Europe Human Primary Cell Production (Million Cells) By Type, 17-25
    4.3. BLOOD (PERIPHERAL) CELLS
    4.3.1. Market Growth Indicators
    4.3.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.4. ENDOTHELIAL CELLS
    4.4.1. Market Growth Indicators
    4.4.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.5. EPITHELIAL CELLS
    4.5.1. Market Growth Indicators
    4.5.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.6. FIBROBLAST CELLS
    4.6.1. Market Growth Indicators
    4.6.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.7. HEPACTOCYTE CELLS
    4.7.1. Market Growth Indicators
    4.7.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.8. KERATINOCYTE CELLS
    4.8.1. Market Growth Indicators
    4.8.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.9. MELANOCYTE CELLS
    4.9.1. Market Growth Indicators
    4.9.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.10. PANCREATIC CELLS
    4.10.1. Market Growth Indicators
    4.10.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.11. SMOOTH MUSCLE CELLS
    4.11.1. Market Growth Indicators
    4.11.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.12. SKELETAL CELLS
    4.12.1. Market Growth Indicators
    4.12.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
    4.13. ADIPOCYTE CELLS
    4.13.1. Market Growth Indicators
    4.13.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25

    CHAPTER 5. EUROPE HUMAN PRIMARY CELL MARKET BY APPLICATION
    5.1. SEGMENT OUTLINE AND MARKET SHARE BY APPLICATION 52
    5.2. EUROPE HUMAN PRIMARY CELL MARKET REVENUE (MILLION USD) BY APPLICATION, 17-25
    5.3. CLINICAL
    5.3.1. Market growth indicators
    5.3.2. Market revenue (Million USD), 17 – 25
    5.4. MEDICAL 55
    5.4.1. Market growth indicators
    5.4.2. Market revenue (Million USD), 17 – 25
    5.5. ESTIMATED SHARE (%) OF HUMAN PRIMARY CELL TYPES IN POTENTIAL APPLICATIONS

    CHAPTER 6. EUROPE HUMAN PRIMARY CELL MARKET BY COUNTRIES
    6.1. SEGMENT OUTLINE AND MARKET SHARE BY COUNTRIES
    6.2. EUROPE HUMAN PRIMARY CELL MARKET REVENUE, PRODUCTION & SALES BY COUNTRIES, 17-25
    6.2.1. Europe Human Primary Cell Market Revenue (Million USD) By Countries, 17-25
    6.2.2. Europe Human Primary Cell Production (Million Cells) By Countries, 17-25
    6.2.3. Europe Human Primary Cell Market Sales (Million Cells) By Countries, 17-25
    6.3. GERMANY 63
    6.3.1. List of Potential Human Primary Cells Customers in Germany
    6.3.2. Germany Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    6.3.3. Germany Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    6.3.4. Germany Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
    6.4. FRANCE 68
    6.4.1. List of Potential Human Primary Cells Customers in France
    6.4.2. France Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    6.4.3. France Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25) 71
    6.4.4. France Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
    6.5. UK
    6.5.1. List of Potential Human Primary Cells Customers in UK
    6.5.2. UK Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    6.5.3. UK Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    6.5.4. UK Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
    6.6. ITALY
    6.6.1. List of Potential Human Primary Cells Customers in Italy
    6.6.2. Italy Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    6.6.3. Italy Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    6.6.4. Italy Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
    6.7. SPAIN 82
    6.7.1. List of Potential Human Primary Cells Customers in Spain
    6.7.2. Spain Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    6.7.3. Spain Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    6.7.4. Spain Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
    6.8. BENELUX 86
    6.8.1. List of Potential Human Primary Cells Customers in Benelux
    6.8.2. Benelux Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    6.8.3. Benelux Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    6.8.4. Benelux Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
    6.9. RUSSIA 92
    6.9.1. List of Potential Human Primary Cells Customers in Russia
    6.9.2. Russia Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    6.9.3. Russia Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    6.9.4. Russia Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
    6.10. REST OF EUROPE 97
    6.10.1. List of Potential Human Primary Cells Customers in Rest of Europe
    6.10.2. Rest of Europe Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    6.10.3. Rest of Europe Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    6.10.4. Rest of Europe Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)

    CHAPTER 7. EUROPE HUMAN PRIMARY CELLS MANUFACTURERS PROFILES/ANALYSIS
    7.1. LONZA 102
    7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.1.2. Human Primary Cells Product Category, Application and Specification
    7.1.2.1. HUMAN BONE MARROW CD+ PROGENITOR CELLS 103
    7.1.2.2. HUMAN PERIPHERAL BLOOD CD14+ MONOCYTES CELLS
    7.1.2.3. DERMAL MICROVASCULAR ENDOTHELIAL CELLS
    7.1.2.4. HUMAN SKELETAL MUSCLE MYOBLASTS
    7.1.2.5. HUMAN LUNG FIBROBLASTS
    7.1.2.6. OTHER PRODUCTS
    7.1.3. Business Overview
    7.2. THERMO FISHER SCIENTIFIC
    7.2.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.2.2. Human Primary Cells Product Category, Application and Specification
    7.2.2.1. Human Mammary Epithelial Cells (HMEC)
    7.2.2.2. Human Umbilical Vein Endothelial Cells (HUVEC )
    7.2.3. Fibroblasts
    7.2.4. Human Skeletal Myoblasts
    7.2.5. Human Plateable Hepatocytes, 5-Donor
    7.2.6. Other Products
    7.2.7. Main Business/Business Overview
    7.3. SIGMA-ALDRICH
    7.3.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.3.2. Human Primary Cells Product Category, Application and Specification
    7.3.2.1. Cryoplateable Primary Human Hepatocytes (MTOXH1002)
    7.3.2.2. Cryopreserved Primary Human Hepatocytes Juvenile (MTOXH1012)
    7.3.2.3. Human Aortic Endothelial Cells (HAOEC)
    7.3.2.4. Human Peripheral Blood T Cells (HPBT)
    7.3.3. Main Business/Business Overview 109
    7.4. CELL BIOLOGICS
    7.4.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.4.2. Human Primary Cells Product Category, Application and Specification
    7.4.2.1. HUMAN PRIMARY AORTIC ENDOTHELIAL CELLS
    7.4.2.2. HUMAN PRIMARY AORTIC FIBROBLASTS
    7.4.2.3. Human Hepatic Stellate Cells
    7.4.2.4. Human Primary Alveolar Epithelial Cells
    7.4.3. Main Business/Business Overview
    7.5. PROMOCELL GMBH
    7.5.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.5.2. Human Primary Cells Product Category, Application and Specification
    7.5.2.1. Melanocytes
    7.5.2.2. Cardiac Myocytes
    7.5.2.3. Skeletal Muscle Cells
    7.5.2.4. Osteoblasts
    7.5.3. Other Products
    7.5.4. Main Business/Business Overview
    7.6. CURELINE
    7.6.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.6.2. Human Primary Cells Product Category, Application and Specification
    7.6.2.1. Primary Cell Lines
    7.6.3. Main Business/Business Overview
    7.7. ZEN-BIO 116
    7.7.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.7.2. Human Primary Cells Product Category, Application and Specification
    7.7.2.1. Human Adult Melanocytes
    7.7.2.2. Adult Stem Cells
    7.7.2.3. Human Dermal Fibroblasts
    7.7.2.4. Human Mesothelial Cells
    7.7.3. Other Products
    7.7.4. Main Business/Business Overview
    7.8. STEMCELL TECHNOLOGIES
    7.8.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.8.2. Human Primary Cells Product Category, Application and Specification
    7.8.2.1. Human Peripheral Blood Monocytes
    7.8.2.2. Human Platelet Lysate, Fibrinogen-Depleted
    7.8.2.3. Human Cord Blood Mononuclear Cells
    7.8.2.4. iCell® Cardiac Progenitor Cells
    7.8.3. Other Products
    7.8.4. Main Business/Business Overview
    7.9. CELL APPLICATIONS
    7.9.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    7.9.2. Human Primary Cells Product Category, Application and Specification
    7.9.2.1. Human Hair Follicle Dermal Papilla Cells
    7.9.2.2. Chondrocyte
    7.9.2.3. Keratinocyte
    7.9.3. Other Products 1
    7.9.4. Main Business/Business Overview
    7.10. CREATIVE BIOARRAY
    7.10.1. COMPANY BASIC INFORMATION, MANUFACTURING BASE, SALES AREA AND ITS COMPETITORS
    7.10.2. HUMAN PRIMARY CELLS PRODUCT CATEGORY, APPLICATION AND SPECIFICATION
    7.10.2.1. Human Synovial Membrane Fibroblasts
    7.10.2.2. Human Leptomeningeal Pericytes
    7.10.2.3. ADIPOSE CELLS
    7.10.2.4. SKELETAL CELLS
    7.10.2.5. PERIPHERAL BLOOD CELLS
    7.10.3. Other Products
    7.10.4. Main Business/Business Overview
    7.11. REPROCELL EUROPE LTD.
    7.11.1. COMPANY BASIC INFORMATION, MANUFACTURING BASE, SALES AREA AND ITS COMPETITORS
    7.11.2. HUMAN PRIMARY CELLS PRODUCT CATEGORY, APPLICATION AND SPECIFICATION
    7.11.2.1. ES/IPS CELLS
    7.11.2.2. IMATRIX-2 STEM CELL CULTURE SUBSTRATE
    7.11.3. Main Business/Business Overview
    7.12. TEBU-BIO
    7.12.1. COMPANY BASIC INFORMATION, MANUFACTURING BASE, SALES AREA AND ITS COMPETITORS
    7.12.2. HUMAN PRIMARY CELLS PRODUCT CATEGORY, APPLICATION AND SPECIFICATION
    7.12.2.1. Human Aortic Endothelial Cells
    7.12.2.2. HUMAN BRONCHIAL EPITHELIAL CELL
    7.12.2.3. Human SMOOTH MUSCLE CELLS
    7.12.3. Other Products
    7.12.4. Main Business/Business Overview

    CHAPTER 8. MARKET SHARE OF KEY VENDORS
    8.1.1. Market Share of Key Vendors

    keyboard_arrow_up
  • • Lonza
    • Thermo Fisher Scientific
    • Sigma-Aldrich
    • Cell Biologics
    • Promocell GmbH
    • Cureline
    • Zen-Bio
    • Stemcell Technologies
    • Cell Applications
    • Creative Bioarray
    • Reprocell Europe Ltd
    • Tebu-Bio

    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Information does this report contain?

• What was the market size of the Europe Human Primary Cells Market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the Europe Human Primary Cells Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

You may also like

CLIENTS

SHARE YOUR CART